Antibiotic persistence of intracellular Brucella abortus.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
01
05
2022
accepted:
05
07
2022
revised:
05
08
2022
pubmed:
27
7
2022
medline:
10
8
2022
entrez:
26
7
2022
Statut:
epublish
Résumé
Human brucellosis caused by the facultative intracellular pathogen Brucella spp. is an endemic bacterial zoonosis manifesting as acute or chronic infections with high morbidity. Treatment typically involves a combination therapy of two antibiotics for several weeks to months, but despite this harsh treatment relapses occur at a rate of 5-15%. Although poor compliance and reinfection may account for a fraction of the observed relapse cases, it is apparent that the properties of the infectious agent itself may play a decisive role in this phenomenon. We used B. abortus carrying a dual reporter in a macrophage infection model to gain a better understanding of the efficacy of recommended therapies in cellulo. For this we used automated fluorescent microscopy as a prime read-out and developed specific CellProfiler pipelines to score infected macrophages at the population and the single cell level. Combining microscopy of constitutive and induced reporters with classical CFU determination, we quantified the protective nature of the Brucella intracellular lifestyle to various antibiotics and the ability of B. abortus to persist in cellulo despite harsh antibiotic treatments. We demonstrate that treatment of infected macrophages with antibiotics at recommended concentrations fails to fully prevent growth and persistence of B. abortus in cellulo, which may be explained by a protective nature of the intracellular niche(s). Moreover, we show the presence of bona fide intracellular persisters upon antibiotic treatment, which are metabolically active and retain the full infectious potential, therefore constituting a plausible reservoir for reinfection and relapse. In conclusion, our results highlight the need to extend the spectrum of models to test new antimicrobial therapies for brucellosis to better reflect the in vivo infection environment, and to develop therapeutic approaches targeting the persister subpopulation.
Sections du résumé
BACKGROUND
Human brucellosis caused by the facultative intracellular pathogen Brucella spp. is an endemic bacterial zoonosis manifesting as acute or chronic infections with high morbidity. Treatment typically involves a combination therapy of two antibiotics for several weeks to months, but despite this harsh treatment relapses occur at a rate of 5-15%. Although poor compliance and reinfection may account for a fraction of the observed relapse cases, it is apparent that the properties of the infectious agent itself may play a decisive role in this phenomenon.
METHODOLOGY/PRINCIPAL FINDINGS
We used B. abortus carrying a dual reporter in a macrophage infection model to gain a better understanding of the efficacy of recommended therapies in cellulo. For this we used automated fluorescent microscopy as a prime read-out and developed specific CellProfiler pipelines to score infected macrophages at the population and the single cell level. Combining microscopy of constitutive and induced reporters with classical CFU determination, we quantified the protective nature of the Brucella intracellular lifestyle to various antibiotics and the ability of B. abortus to persist in cellulo despite harsh antibiotic treatments.
CONCLUSION/SIGNIFICANCE
We demonstrate that treatment of infected macrophages with antibiotics at recommended concentrations fails to fully prevent growth and persistence of B. abortus in cellulo, which may be explained by a protective nature of the intracellular niche(s). Moreover, we show the presence of bona fide intracellular persisters upon antibiotic treatment, which are metabolically active and retain the full infectious potential, therefore constituting a plausible reservoir for reinfection and relapse. In conclusion, our results highlight the need to extend the spectrum of models to test new antimicrobial therapies for brucellosis to better reflect the in vivo infection environment, and to develop therapeutic approaches targeting the persister subpopulation.
Identifiants
pubmed: 35881641
doi: 10.1371/journal.pntd.0010635
pii: PNTD-D-22-00558
pmc: PMC9355222
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0010635Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Microbiol Spectr. 2016 Jun;4(3):
pubmed: 27337444
Clin Microbiol Rev. 2003 Jan;16(1):65-78
pubmed: 12525425
Front Cell Infect Microbiol. 2013 Jul 08;3:28
pubmed: 23847770
Proc Natl Acad Sci U S A. 2021 Dec 21;118(51):
pubmed: 34911764
Virulence. 2013 May 15;4(4):273-83
pubmed: 23563389
Cell Microbiol. 2011 Aug;13(8):1261-74
pubmed: 21707904
Sci Rep. 2016 Feb 03;6:20519
pubmed: 26837570
Prilozi. 2010;31(1):21-32
pubmed: 20703181
J Biosci. 2008 Nov;33(4):539-47
pubmed: 19208979
Cell Host Microbe. 2012 Jan 19;11(1):33-45
pubmed: 22264511
Cochrane Database Syst Rev. 2012 Oct 17;10:CD007179
pubmed: 23076931
J Bacteriol. 1967 Jan;93(1):445-50
pubmed: 6020415
Sci Rep. 2016 Oct 21;6:35835
pubmed: 27767061
PLoS Negl Trop Dis. 2012;6(10):e1865
pubmed: 23145195
Clin Infect Dis. 1995 May;20(5):1241-9
pubmed: 7620005
Sci Signal. 2019 Jul 30;12(592):
pubmed: 31363068
Cell Microbiol. 2014 Mar;16(3):396-410
pubmed: 24119283
Cell Microbiol. 2001 Jul;3(7):487-97
pubmed: 11437834
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3746-51
pubmed: 20133586
Nat Commun. 2018 May 18;9(1):1993
pubmed: 29777131
J Appl Microbiol. 2000 May;88(5):784-90
pubmed: 10792538
PLoS Med. 2007 Dec;4(12):e317
pubmed: 18162038
Antimicrob Agents Chemother. 2012 May;56(5):2223-30
pubmed: 22391538
Mol Cell. 2019 Oct 17;76(2):255-267
pubmed: 31626749
Expert Rev Anti Infect Ther. 2013 Nov;11(11):1207-14
pubmed: 24073941
Antimicrob Agents Chemother. 1986 Dec;30(6):958-60
pubmed: 3813520
Curr Opin Drug Discov Devel. 2006 Mar;9(2):218-30
pubmed: 16566292
Front Biosci. 2004 May 01;9:1136-56
pubmed: 14977534
N Engl J Med. 2005 Jun 2;352(22):2325-36
pubmed: 15930423
Cell Host Microbe. 2021 Dec 8;29(12):1757-1773.e10
pubmed: 34731646
PLoS Negl Trop Dis. 2020 May 11;14(5):e0008164
pubmed: 32392223
F1000Res. 2019 Oct 21;8:
pubmed: 31737252
Ann Clin Microbiol Antimicrob. 2012 Aug 28;11:24
pubmed: 22929054
Chem Biol. 2014 Apr 24;21(4):509-518
pubmed: 24684906
J Antimicrob Chemother. 1983 Oct;12 Suppl C:13-20
pubmed: 6605963
Nat Rev Microbiol. 2019 Jul;17(7):441-448
pubmed: 30980069
Trends Microbiol. 1999 Apr;7(4):149-54
pubmed: 10217829
Yale J Biol Med. 1958 Feb;30(4):257-91
pubmed: 13531168
Antimicrob Resist Infect Control. 2017 Dec 28;6:130
pubmed: 29299304
J Bacteriol. 2010 Dec;192(23):6191-9
pubmed: 20935098
Lancet Infect Dis. 2006 Feb;6(2):91-9
pubmed: 16439329
Antimicrob Agents Chemother. 1986 Aug;30(2):260-6
pubmed: 3094438
J Bacteriol. 2000 Sep;182(17):4849-55
pubmed: 10940027
Res Microbiol. 2006 Mar;157(2):93-8
pubmed: 16364608
World Health Organ Tech Rep Ser. 1986;740:1-132
pubmed: 3097967
Turk J Med Sci. 2014;44(2):220-3
pubmed: 25536728
PLoS Pathog. 2009 Oct;5(10):e1000645
pubmed: 19876393
Antimicrob Agents Chemother. 2013 Jul;57(7):3230-9
pubmed: 23629720
Mol Microbiol. 1999 Sep;33(6):1210-20
pubmed: 10510235
PLoS One. 2020 Sep 22;15(9):e0239147
pubmed: 32960928
Cell Microbiol. 2015 Jul;17(7):951-8
pubmed: 25916795
FEMS Microbiol Rev. 2010 May;34(3):379-94
pubmed: 20180858
Clin Infect Dis. 2006 Apr 15;42(8):1075-80
pubmed: 16575723
Vet Microbiol. 2010 Jan 27;140(3-4):392-8
pubmed: 19604656
Cell Microbiol. 2011 Jul;13(7):1044-58
pubmed: 21501366
Nat Med. 2005 Oct;11(10):1082-7
pubmed: 16200071
J Antimicrob Chemother. 2006 Aug;58(2):256-65
pubmed: 16816396
J Exp Med. 2003 Aug 18;198(4):545-56
pubmed: 12925673
FEMS Microbiol Rev. 2019 Jul 1;43(4):341-361
pubmed: 30916769
PLoS Pathog. 2008 Feb 8;4(2):e21
pubmed: 18266466
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0146821
pubmed: 34570646
J Exp Med. 2016 May 2;213(5):809-25
pubmed: 27114608
FEMS Microbiol Rev. 2017 May 1;41(3):219-251
pubmed: 28333307
BMC Infect Dis. 2003 Apr 28;3:5
pubmed: 12718759
Clin Pharmacokinet. 1978 Mar-Apr;3(2):108-27
pubmed: 346286
Front Cell Infect Microbiol. 2018 Apr 20;8:103
pubmed: 29732320
Molecules. 2020 Jul 17;25(14):
pubmed: 32708842
Tuberculosis (Edinb). 2007 May;87(3):248-55
pubmed: 17258938
Antimicrob Agents Chemother. 2015 Dec;59(12):7517-29
pubmed: 26392509
PLoS Pathog. 2013;9(8):e1003556
pubmed: 23950720
Antimicrob Agents Chemother. 2013 Jul;57(7):3326-33
pubmed: 23650167
PLoS Negl Trop Dis. 2018 May 10;12(5):e0006488
pubmed: 29746469
Br J Pharmacol. 2017 Jul;174(14):2225-2236
pubmed: 27925153
Science. 2014 Jan 10;343(6167):204-8
pubmed: 24408438
BMC Infect Dis. 2018 Jan 16;18(1):43
pubmed: 29338693
Iran Biomed J. ;22(4):275-82
pubmed: 29031243
Cell Host Microbe. 2015 Jan 14;17(1):32-46
pubmed: 25543231
Expert Rev Anti Infect Ther. 2008 Feb;6(1):109-20
pubmed: 18251668
PLoS Biol. 2014 Feb 18;12(2):e1001793
pubmed: 24558351
Microb Pathog. 2020 Jul;144:104194
pubmed: 32289464
Sci Rep. 2019 Dec 2;9(1):18132
pubmed: 31792307
J Infect Chemother. 2012 Feb;18(1):41-6
pubmed: 21826587
Int J Med Microbiol. 2018 Jan;308(1):49-57
pubmed: 28865995
Iran J Pathol. 2020 Spring;15(2):127-133
pubmed: 32215028
J Antimicrob Chemother. 2005 Apr;55(4):511-7
pubmed: 15731197
mBio. 2019 Jul 23;10(4):
pubmed: 31337727
J Exp Med. 1953 Jan;97(1):77-90
pubmed: 13022864
Caspian J Intern Med. 2013 Spring;4(2):636-41
pubmed: 24009951
Int J Antimicrob Agents. 2005 Aug;26(2):101-5
pubmed: 16039098
PLoS One. 2015 Apr 28;10(4):e0121790
pubmed: 25919005
Trends Microbiol. 2022 May;30(5):466-479
pubmed: 34753652
Vet Microbiol. 2002 Dec 20;90(1-4):479-96
pubmed: 12414166
J Vis Exp. 2016 Aug 05;(114):
pubmed: 27584799
J Cell Sci. 2018 Feb 22;131(4):
pubmed: 29361547
Infect Immun. 1998 Dec;66(12):5711-24
pubmed: 9826346
J Clin Microbiol. 2004 Dec;42(12):5439-43
pubmed: 15583262
FEMS Microbiol Rev. 2018 Jul 1;42(4):425-447
pubmed: 29596635
Rev Sci Tech. 2013 Apr;32(1):249-61
pubmed: 23837382
Infect Ecol Epidemiol. 2018 Jul 24;8(1):1500846
pubmed: 30083304
Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1673-8
pubmed: 15632218
Infect Dis Clin North Am. 2003 Sep;17(3):615-34
pubmed: 14711080
Int J Infect Dis. 2010 Jun;14(6):e469-78
pubmed: 19910232
Clin Infect Dis. 2009 Jul 1;49(1):142-7
pubmed: 19480580
Pathogens. 2021 Feb 09;10(2):
pubmed: 33572264
Microbiology (Reading). 2019 Jan;165(1):1-3
pubmed: 30422108
Cell Microbiol. 2001 Mar;3(3):159-68
pubmed: 11260139
Prev Vet Med. 2015 May 1;119(3-4):211-5
pubmed: 25835775
Microbiology (Reading). 2016 Jun;162(6):966-978
pubmed: 27027532
Mol Microbiol. 2008 Dec;70(6):1378-96
pubmed: 19019140
BMC Public Health. 2018 Jan 11;18(1):125
pubmed: 29325516
Curr Top Microbiol Immunol. 2008;322:107-31
pubmed: 18453274
Nat Commun. 2020 May 4;11(1):2200
pubmed: 32366839
Nature. 2013 Nov 21;503(7476):365-70
pubmed: 24226776
PLoS One. 2012;7(2):e32090
pubmed: 22393379
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0067321
pubmed: 34370577
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0106121
pubmed: 34543094
Genome Biol. 2006;7(10):R100
pubmed: 17076895